GenScript Bio (01548): CARVYKTI generated approximately $555 million in net sales for the fourth quarter.

date
21:01 21/01/2026
avatar
GMT Eight
Kingsway Biotech (01548) released an announcement that, based on the cooperation and licensing agreement signed between Legend and Janssen Biotech, Inc. on December 21, 2017, CARVYKTI is expected to generate approximately $555 million in net sales from trade by the end of the quarter ending December 31, 2025.
GENSCRIPT BIO (01548) announced that, based on the collaboration and licensing agreement established with Legend and Janssen Biotech, Inc. (Johnson & Johnson) on December 21, 2017, CARVYKTI generated approximately 550 million US dollars in net sales in the quarter ending December 31, 2025.